218 related articles for article (PubMed ID: 38036539)
1. Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors.
Su X; Lu X; Bazai SK; Dainese L; Verschuur A; Dumont B; Mouawad R; Xu L; Cheng W; Yan F; Irtan S; Lindner V; Paillard C; Le Bouc Y; Coulomb A; Malouf GG
Nat Commun; 2023 Nov; 14(1):7884. PubMed ID: 38036539
[TBL] [Abstract][Full Text] [Related]
2. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
[TBL] [Abstract][Full Text] [Related]
3. [Wilms' tumor: reached progress and future prospects].
Tamaro P
Arch Ital Urol Androl; 1997 Sep; 69(4):227-32. PubMed ID: 9417294
[TBL] [Abstract][Full Text] [Related]
4. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
[TBL] [Abstract][Full Text] [Related]
6. Bilateral anaplastic Wilms' tumors: change in ploidy following treatment.
Med Pediatr Oncol; 1987; 15(1):28-30. PubMed ID: 3031438
[No Abstract] [Full Text] [Related]
7. Current standards of care and future directions for "high-risk" pediatric renal tumors: Anaplastic Wilms tumor and Rhabdoid tumor.
Geller JI
Urol Oncol; 2016 Jan; 34(1):50-6. PubMed ID: 26612481
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
9. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
10. Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.
Rastegar B; Andersson N; Petersson A; Karlsson J; Chattopadhyay S; Valind A; Jansson C; Durand G; Romerius P; Jirström K; Holmquist Mengelbier L; Gisselsson D
Clin Cancer Res; 2023 Jul; 29(14):2668-2677. PubMed ID: 37140929
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic Wilms' tumor: clinical and pathologic studies.
Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
[TBL] [Abstract][Full Text] [Related]
12. Extrarenal Anaplastic Wilms Tumor: A Case Report With Genomic Analysis and Tumor Models.
Willis KR; Sathe AA; Xing C; Koduru P; Artunduaga M; Butler EB; Park JY; Kurmasheva RT; Houghton PJ; Chen KS; Rakheja D
J Pediatr Hematol Oncol; 2022 May; 44(4):147-154. PubMed ID: 35129140
[TBL] [Abstract][Full Text] [Related]
13. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
14. Management of Wilms tumor: current standard of care.
Sonn G; Shortliffe LM
Nat Clin Pract Urol; 2008 Oct; 5(10):551-60. PubMed ID: 18836464
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
[TBL] [Abstract][Full Text] [Related]
16. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
18. Recent experience with Wilms' tumor: 1978-1991.
Shamberger RC; Macklis RM; Sallan SE
Ann Surg Oncol; 1994 Jan; 1(1):59-65. PubMed ID: 7834430
[TBL] [Abstract][Full Text] [Related]
19. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
